AVTR vs CYRX
AVTR: A global provider of mission-critical products and services for laboratory research and production workflows across biopharma and advanced industries. CYRX: Cryoport is a specialized provider of mission-critical, temperature-controlled supply chain solutions for the fast-growing cell and gene therapy market.
Side-by-side fundamentals
| Metric | AVTR | CYRX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $15.39 | $16.90 | |
| Market cap | $10.5B | $856M | |
| Net margin FY2025, SEC XBRL | -8.1% | +44.4% | CYRX higher |
| Gross margin FY2025, SEC XBRL | +32.7% | +47.1% | CYRX higher |
| Operating margin FY2025, SEC XBRL | -3.8% | -20.9% | AVTR higher |
| ROE FY2025, SEC XBRL | -9.5% | +15.6% | CYRX higher |
| ROA FY2025, SEC XBRL | -4.5% | +10.2% | CYRX higher |
| Debt / equity as of 2026-09-03 | 0.66 | 0.38 | CYRX lower |
| Revenue growth (YoY) as of 2026-09-03 | -1.6% | -8.0% | AVTR higher |
| Revenue CAGR (3y) SEC XBRL | -4.5% | -9.4% | AVTR higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.98 | 1.55 | |
| 1-year return as of 2026-10-08 close | +11.9% | +68.0% | CYRX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.